Didanosine
NDC Package 65862-310-05

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Didanosine is a medication used with other HIV medications to help control HIV infection. Marketed by Aurobindo Pharma Limited, this product is identified by NDC 65862-310 and is authorized under FDA application ANDA090094.

Identification & Billing

NDC Package Code
65862-310-05
Package Description
500 CAPSULE, DELAYED RELEASE in 1 BOTTLE
Product Code
65862-310
11-Digit Billing Format
65862031005

Clinical Specifications

Proprietary Name
Didanosine
Dosage Form
-
Usage Information
This drug is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Didanosine belongs to a class of drugs known as nucleoside reverse transcriptase inhibitors-NRTI. Didanosine is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, do all of the following: (1) continue to take all HIV medications exactly as prescribed by your doctor, (2) always use an effective barrier method (latex or polyurethane condoms/dental dams) during all sexual activity, and (3) do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Regulatory & Marketing

Labeler Name
Aurobindo Pharma Limited
FDA Application #
ANDA090094
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
09-24-2008
End Marketing Date
02-17-2021
Listing Expiration
02-17-2021
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (65862-310). Click a package code to view its specific billing and regulatory data.

65862-310-14
10 BLISTER PACK in 1 CARTON / 14 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK
65862-310-30
30 CAPSULE, DELAYED RELEASE in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 65862-310-05 identifies a specific commercial package of 500 capsule, delayed release in 1 bottle of Didanosine, labeled by Aurobindo Pharma Limited. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Aurobindo Pharma Limited on September 24, 2008. The current certification is valid through February 17, 2021.

What are the primary indications for this medication?

This drug is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Didanosine belongs to a class of drugs known as nucleoside reverse transcriptase inhibitors-NRTI. Didanosine is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, do all of the following: (1) continue to take all HIV medications exactly as prescribed by your doctor, (2) always use an effective barrier method (latex or polyurethane condoms/dental dams) during all sexual activity, and (3) do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

How is this Aurobindo Pharma Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 65862031005. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
65862-310-05
11-Digit CMS (5-4-2)
65862-0310-05

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.